Former U.S. FDA Official Says Congress Should Fix China API Problem
This article was originally published in PharmAsia News
As far back as 1999, U.S. Congress pressed U.S. FDA to deal more effectively with a China-made drug believed to be contaminated and responsible for 17 deaths. In that case, an antibiotic was involved, but today Congress again is investigating why FDA was so late in becoming aware of the link between 19 deaths and a contaminated heparin ingredient produced in China. Former FDA Deputy Commissioner William Hubbard noted the similarities and said the incidents would be repeated "until Congress fixes this problem." (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.